Grass Pollen Allergy Vaccine Successful In Phase IIa Trial

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers...

Source: http://www.medicalnewstoday.com/releases/246659.php

CISCO SYSTEMS INC APPLE INC ELECTRONIC DATA SYSTEMS CORPORATION ORACLE CORP